FibroScan® examination is a non-invasive, fast, and safe method for assessing liver fibrosis and steatosis. Take care of your patients' health today.
Discover innovative diagnostic technology
FibroScan® is a non-invasive method of liver examination, introduced to the market in 2003. It is an alternative to biopsy in cases where the goal of the procedure is to assess the advancement of structural changes in the liver during chronic inflammation of various etiologies. FibroScan® enables immediate diagnostics.
The FibroScan® method is based on Vibration Controlled Transient Elastography (VCTE™) technology. The device probe generates a mechanical impulse that propagates deep into the liver. The speed of this wave's movement depends on the liver's consistency ("stiffness"). This stiffness increases directly proportionally to the degree of fibrosis advancement.
Advanced diagnostic capabilities in one device
LSM using the VCTE™ method measures stiffness at a shear wave frequency of 50 Hz. It is the standard for non-invasive assessment of liver stiffness and a marker of liver fibrosis, appropriate for all chronic liver diseases.
CAP (dB/m) measures the attenuation of ultrasound sent into the liver. It is a marker of liver steatosis. The CAP measurement range is from 100 to 400 dB/m.
SSM measures stiffness in kPa at a shear wave frequency of 100 Hz. It is a marker of portal hypertension and is used for risk stratification of complications of liver cirrhosis and monitoring esophageal varices.
Why doctors choose FibroScan®
Fibrosis measurement is completely non-invasive, does not involve tissue damage or blood sampling. There are practically no absolute contraindications to the examination, and its performance carries no risks.
Numerous scientific studies have shown high consistency in determining the degree of fibrosis advancement between the elastography method and histopathological examination of liver biopsy.
The examination result is obtained immediately after its performance, allowing for quick diagnosis and treatment planning.
The result is an average of 10 measurements, which ensures an objective assessment and minimizes the risk of error.
Elastography examination results are significantly less influenced by coexisting diseases, metabolic disorders, or medications used compared to biochemical methods of fibrosis assessment.
FibroScan® can be used not only for diagnosis in patients with recognized disease but also for screening to detect asymptomatic liver damage at an early stage.
FibroScan® offers wide diagnostic possibilities in many liver diseases
Assessment of fibrosis stage in patients with HBV and HCV infection. Monitoring disease progression and response to antiviral treatment.
Quantitative assessment of steatosis (CAP) and fibrosis. Identification of patients with NASH and advanced fibrosis requiring further diagnostics.
Diagnosis and monitoring of patients with ALD. Early detection of cirrhosis, allowing for prevention of complications and appropriate therapeutic management.
Monitoring fibrosis progression in autoimmune hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC).
Monitoring for recurrence of the underlying disease or development of complications after liver transplantation, such as rejection-related fibrosis or recurrence of viral hepatitis.
Early identification of patients with asymptomatic liver damage, especially in risk groups (type 2 diabetes, obesity, metabolic syndrome).
FibroScan® is used to assess the degree of fibrosis and/or steatosis in a wide range of liver diseases and clinical situations:
FibroScan® examination is a dedicated system used as an aid in managing patients with confirmed or suspected chronic liver diseases. It helps assess fibrosis, steatosis, and the likelihood of cirrhosis and its complications (in the case of the 630 Expert model).
Detailed data for specialists
| Fibrosis stage | Value (kPa) | Clinical interpretation |
|---|---|---|
| F0-F1 | <7.0 | No or minimal fibrosis |
| F2 | 7.0-9.5 | Moderate fibrosis |
| F3 | 9.5-12.5 | Advanced fibrosis |
| F4 | >12.5 | Liver cirrhosis |
* Cut-off values may vary depending on the etiology of liver disease
FibroScan uses Vibration-Controlled Transient Elastography (VCTE), which allows for measuring liver stiffness by assessing the propagation speed of a mechanical wave in liver tissue. Results are expressed in kilopascals (kPa).
| Steatosis stage | CAP Value (dB/m) | Interpretation |
|---|---|---|
| S0 | <238 | No steatosis (<10%) |
| S1 | 238-259 | Mild steatosis (11-33%) |
| S2 | 260-290 | Moderate steatosis (34-66%) |
| S3 | >290 | Severe steatosis (>67%) |
Comprehensive support for professionals
Echosens provides comprehensive support for FibroScan® operators:
Additionally, a free myFibroScan mobile application is available for iOS and Android:
Note: These tools are intended for licensed healthcare professionals and do not replace personalized medical advice. They should not be the sole basis for clinical decisions.
The crucial role of the specialist in the diagnostic process
Recognition in international guidelines
EASL recommends non-invasive methods for assessing fibrosis, including FibroScan, as the first line of diagnosis in chronic liver diseases. Liver biopsy is recommended in cases of ambiguous non-invasive test results or suspicion of coexisting pathologies.
AASLD recognizes FibroScan examination as a useful tool in assessing liver fibrosis in patients with chronic hepatitis B and C and NAFLD. It recommends combining different non-invasive methods to increase diagnostic accuracy.
WHO recommends the use of non-invasive methods for assessing liver fibrosis, including FibroScan, in the diagnosis and monitoring of patients with chronic hepatitis B and C, especially in countries with limited access to specialized healthcare.
Studies confirming the effectiveness of the method
Sandrin L, et al.
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-1713.
First publication describing the FibroScan technology
European Association for Study of Liver, et al.
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-264.
Comprehensive guidelines on non-invasive liver diagnostics
Wong VW, et al.
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462.
Application of FibroScan in NAFLD
Tsochatzis EA, et al.
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-659.
Meta-analysis on the diagnostic accuracy of elastography
Karlas T, et al.
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66:1022-1030.
Meta-analysis regarding CAP technology in steatosis assessment
Real-world cases from medical practice
Male, 52 years old
Patient with newly diagnosed HCV infection, genotype 1b. Laboratory tests showed elevated AlAT (82 U/l) and AspAT (64 U/l) activity. FibroScan examination showed liver stiffness at 8.2 kPa (F2) and CAP 245 dB/m (S1).
Conclusions: Based on FibroScan results, the patient was qualified for antiviral treatment without the need for a biopsy. After completing therapy, the patient achieved SVR (sustained virological response), and a control FibroScan examination showed a decrease in liver stiffness to 6.8 kPa.
Female, 48 years old
Patient with obesity (BMI 33.2 kg/m²), type 2 diabetes, and hyperlipidemia. Laboratory tests showed slightly elevated liver enzyme values. FibroScan examination showed liver stiffness of 13.2 kPa (F4) and CAP 320 dB/m (S3).
Conclusions: Based on FibroScan results, non-alcoholic steatohepatitis (NASH) with cirrhosis was diagnosed. The patient was referred for screening for hepatocellular carcinoma and esophageal varices. An intensive weight reduction and lifestyle modification program was implemented.